Which tinnitus treatments did Dr. Oz promote specifically on The Dr. Oz Show episodes?
Executive summary
Dr. Mehmet Oz has discussed a small set of tinnitus-related approaches on his platforms: coverage of transcranial magnetic stimulation (TMS) and other emerging therapies in written/TV-adjacent pieces with Dr. Michael Roizen, promotion of hearing‑technology vendors such as ReSound during CES coverage on The Dr. Oz Show, and—according to online forum reporting—an alleged association with an infomercial for a supplement called Audizen that forum users flagged as dubious [1] [2] [3]. Available sources do not provide a comprehensive, episode‑by‑episode inventory, so conclusions are limited to items explicitly documented in the reporting provided [3] [1] [2].
1. Dr. Oz’s public discussion of transcranial magnetic stimulation (TMS)
Dr. Oz, together with Dr. Michael Roizen in syndicated columns and media pieces, raised TMS as a potential treatment avenue for some tinnitus sufferers, noting Loyola University research exploring whether TMS could help patients who have both tinnitus and depression—an example of discussing investigational neuromodulation rather than declaring a definitive cure [1]. The coverage framed TMS as an area of active research and invited readers to “stay tuned,” which signals attention to experimental clinical work rather than unequivocal promotion of an over‑the‑counter fix [1].
2. Coverage of hearing‑technology innovations (ReSound at CES)
The Dr. Oz Show aired a segment summarizing innovative health care technologies at CES in which ReSound’s “Smart Hearing” products were featured, meaning the program gave airtime to a commercial hearing‑technology vendor as part of a technology roundup—coverage that can function as endorsement in the eyes of viewers even if framed as reporting on gadgets [2]. That segment explicitly linked the show to consumer hearing solutions and industry booths at trade shows rather than to clinical treatment protocols judged by randomized trials [2].
3. Advice to seek standard clinical care and behavioral options
In syndicated health columns authored by Roizen and Oz, readers are advised to consult physicians or specialists about treatment options and referrals to tinnitus experts, with mention of resources such as the Hearing Loss Association of America and cognitive behavioral therapy referrals—suggesting the hosts sometimes emphasized standard clinical pathways like hearing‑aid access and CBT over miracle cures [4]. The columns reviewed causes and common clinical approaches to tinnitus, positioning the duo as encouraging mainstream evaluation rather than home remedies [4].
4. Questionable supplement claims and the Audizen thread
Online forum commentary flagged an infomercial for a supplement marketed as “Audizen” that purportedly used Dr. Oz’s name or implied his endorsement; forum posters called that linkage a red flag and disputed the product’s claims, while noting confusion over whether Oz was legitimately promoting the product [3]. The forum piece highlights how Dr. Oz’s name can be invoked in third‑party advertising and how such uses generate skepticism among tinnitus sufferers; the reporting does not establish that The Dr. Oz Show itself ran an Audizen promotion, only that online marketers referenced Oz in ads and forum members questioned that practice [3].
5. What the sources do not show — and why that matters
None of the provided sources supply a complete list of Dr. Oz Show episodes or a definitive, episode‑level catalog of every tinnitus remedy promoted on the program, so it is not possible from these documents alone to assert exhaustively which specific episodes pushed which products or procedures [3] [1] [2]. The evidence supports that The Dr. Oz Show covered emerging neuromodulation research (TMS), showcased commercial hearing‑technology like ReSound during CES coverage, and that the Oz name has been used in online supplement marketing disputed by forum users—but the reporting does not confirm direct, repeated on‑air endorsements of particular pills, drops, or devices beyond the documented CES segment and column discussion [3] [1] [2].